Early Dose Adjustments Help Complete 2-Year Treatment Without Losing Efficacy in High-Risk Node-Positive EBC - Video
Overview
In the video, Dr. Carlos Barrios, director and principal investigator of the oncology research center at Hospital São Lucas, and president of the Latin American Cooperative Oncology Group in Porto Alegre, Brazil, explains safety profile of Ramiven in patients with node-positive, high-risk, hormone receptor positive early breast cancer. Over two years, Ramiven provides lasting protection for patients with node-positive, high-risk early breast cancer1.
Ramiven has a reversible and manageable safety profile with most adverse events being predictable, transient and low-grade.
Grade 3 diarrhea was reported reported by 7.8% of patients in Ramiven plus endocrine therapy with no grade 4 diarrhea reported2,3. Diarrhea typically occurs early within the first 8 days and last about 5-6 days with appropriate management. Proactive care is key. Clear guidance, early follow-up, and ensuring patients have anti-diarrheals can help them stay on treatment4,5.
If needed, dose adjustments can help patients complete their two-year course without compromising efficacy6. By managing side effects early, you help patients benefit from 2 years of treatment with Ramiven and endocrine therapy with a deepening effect at 5 years1,4,7. Ramiven in combinations with endocrine therapy provides protection during the critical first 2 years with carryover effect at 5 years. These benefits support the use of Ramiven in early breast cancer patients at high risk of recurrence1,2,7,8,9,10.
References:
1. Rastogi P, et al. J Clin Oncol. 2024;42(9):987–93. 2. Johnston SRD, et al. Lancet Oncol. 2023;24(1):77–90. 3 Tolaney SM, et al. Eur J Cancer. 2024;199:113555. 4. Johnston SRD, et al. J Clin Oncol. 2020;38(34):3987–98. 5. Rugo HS, et al. Ann Oncol. 2022;33(6):616–27. 6. Goetz MP, et al. NPJ Breast Cancer. 2024;10(1):34 (+Suppl. Appendix). 7.Ramiven India Abridged PI, Version Control No. - PA008SPIN05. 8. Freedman RA, et al. J Clin Oncol. 2024;42(18):2233–5. 9. Loibl S, et al. Ann Oncol. 2024;35(2):159–82. 10. Curigliano G, et al. Ann Oncol. 2023;34(11):970–86.
PP-AL-IN-1754 | 03/10/2025
Eli Lilly and Company (India) Private Limited
For further Information about Lilly and Lilly products please contact us at the below address: Plot 92, Sector 32 Gurgaon, Haryana, 122001, India Ph.: +91-124-4753000/01 | www.lilly.com/in
For adverse events and safety reporting, please reach out to: mailbox_in-gps@lilly.com | For any additional information related to Lilly products, please reach out to: queries_in-medinfo@lilly.com.
This material (including any link) is intended solely for the use of the recipient(s) and may contain confidential information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please notify the sender immediately and destroy all copies of the material. The information provided in this section is intended solely for the use of registered medical practitioner. This material is being provided to healthcare professionals only for their guidance and use. Nothing on this website/microsite/material should be construed as giving medical advice or making recommendations regarding any health-related decision or action.
© 2025 Eli Lilly and Company
